P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when?
Christopher W Good1, Peter B Berger
1Geisinger Center for Clinical Studies, MC 40-04, Danville, PA 17822, USA.
Insights
This review examines P2Y12 antagonists for acute coronary syndromes. It details optimal use of these antiplatelet agents, including patient selection, timing, drug choice, and dosage.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute coronary syndromes (ACS) result from reduced myocardial blood flow, often due to atherosclerotic plaque rupture and thrombus formation.
- Current treatments involve antithrombotic therapy (anticoagulant and antiplatelet) and percutaneous coronary interventions with stenting.
Purpose of the Study:
- To review the role of P2Y12 antagonists in antiplatelet therapy for ACS.
- To provide guidance on the optimal use of P2Y12 antagonists regarding patient selection, timing, agent choice, and dosage.
Main Methods:
- Literature review of clinical data on P2Y12 antagonists in ACS management.
- Analysis of evidence supporting specific therapeutic strategies.
Main Results:
- P2Y12 antagonists are a critical component of antiplatelet therapy in ACS.
- Evidence guides decisions on when to initiate therapy, which agent to use, and at what dose.
Conclusions:
- Optimizing P2Y12 antagonist therapy is essential for managing ACS.
- This review synthesizes current data to inform clinical practice for these agents.
Abstract:
Acute coronary syndromes reflect a spectrum of disease related, most commonly, to the sudden reduction in blood flow to a portion of myocardium. The underlying pathogenesis of the reduction in coronary flow is related to the sudden rupture of an atherosclerotic plaque, with subsequent thrombus formation leading to either vascular occlusion or microembolization. Clinicians combat this process with antithrombotic therapy, which typically includes both anticoagulant and antiplatelet therapy, and mechanical therapies, such as percutaneous coronary interventions, nearly always using stents. This review focuses on P2Y12 antagonists as one component of our armamentarium of antiplatelet therapies, specifically on data addressing in whom, when, which agent, and in what dose such agents should be administered.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...